The role of serum and urinary carbohydrate antigen 19-9 in predicting renal injury associated with ureteral stone

Abstract

This study was designed to evaluate the role of urinary and serum carbohydrate antigen 19-9 (CA19-9) as a biomarker in the assessment of patients with ureteral stone. A total of 38 patients with ureteral stone and hydronephrosis who underwent transurethral lithotripsy (TUL) (Group A) and 24 age-matched healthy controls (Group B) were evaluated in this study. Urinary and serum CA19-9 concentrations were measured in group A patients before TUL as well as 4 and 8 weeks following the operation. Urinary and serum CA19-9 concentrations were also measured in group B participants. Median concentration of urinary and serum CA19-9 was 34.0 and 15.0 kU/L in group A patients and 16.1 and 5.3 kU/L in group B, respectively (p < 0.001). Medians of CA19-9 concentration in urine and serum reduced to 12.5 and 4.5 kU/L 8 weeks after TUL (p < 0.001). Following successful TUL and hydronephrosis resolution, a significant decline was detected in serum and urinary CA19-9. We also noted that duration of ureteral obstruction was associated with serum and urinary CA19-9 concentrations, suggesting the potential role of this marker in predicting renal damage associated with urinary tract obstruction and determining the appropriate timing of interventions.

Diagnostic value of elevated serum carbohydrate antigen 199 level in acute cholangitis secondary to choledocholithiasis

“…As one of the common tumor markers, CA199 is mainly used in the auxiliary diagnosis and evaluation of disease progression and prognosis of pancreatic cancer, colorectal cancer, and other diseases[ 12 - 13 ]. In recent years, the abnormally elevated CA199 in some non-cancerous benign diseases has drawn increasing attention[ 14 - 16 ]. However, the role of elevated serum CA199 in the diagnosis of acute cholangitis secondary to choledocholithiasis deserves further studies.…”

A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case–control study

“…Interestingly, urinary CA19-9 was found to be superior to its serum counterpart in the diagnosis of low-grade and early stages of TCC of urinary bladder [58]. Increased levels of CA19-9 were seen in urine due to urothelial obstruction [59] and renal injury [60], indicating the local production and secretion of this glycolipid into urine. Our inability to detect significant differences in CA19-9 expression in our experiments using pancreatic samples could therefore be due to either limited passage of this molecule through the glomerular barrier or post-translational modification or proteolytic processing that lead to masking, alteration, or loss of the epitopes recognised by currently available antibodies.…”